: Delayed puberty (DP) defines a retardation of onset/progression of sexual maturation beyond the expected age due to either a lack/delay of the hypothalamo-pituitary-gonadal (HPG) axis activation or a gonadal failure. DP usually gives rise to concern and uncertainty in patients and their families, potentially affecting their immediate psychosocial well-being and also creating longer-term psychosexual sequelae. The most frequent form of DP in younger teenagers is self-limiting and may not need any intervention. Conversely, DP due to hypogonadism requires prompt and specific treatment that we summarize in this review. Hormone therapy primarily targets genital maturation, development of secondary sexual characteristics and the achievement of target height in line with genetic potential, but other key standards of care include body composition and bone mass. Finally, pubertal induction should promote psychosexual development and mitigate both short- and long-term impairments comprising low self-esteem, social withdrawal, depression and psychosexual difficulties. Different therapeutic options for pubertal induction have been described for both males and females but we lack the necessary larger randomized trials to define the best approaches for both sexes. We provide an in-depth and updated literature review regarding therapeutic options for inducing puberty in males and females, particularly focusing on recent therapeutic refinements that better encompass the heterogeneity of this population, and underlining key differences in therapeutic timing and goals. We also highlight persistent shortcomings in clinical practice, wherein strategies directed at "the child with delayed puberty of uncertain aetiology" risk being misapplied to older adolescents likely to have permanent hypogonadism.

New and consolidated therapeutic options for pubertal induction in hypogonadism : in-depth review of the literature / S. Federici, G. Goggi, R. Quinton, L. Giovanelli, L. Persani, B. Cangiano, M. Bonomi. - In: ENDOCRINE REVIEWS. - ISSN 0163-769X. - (2021 Dec 01). [Epub ahead of print] [10.1210/endrev/bnab043]

New and consolidated therapeutic options for pubertal induction in hypogonadism : in-depth review of the literature

S. Federici
Co-primo
;
G. Goggi
Co-primo
;
L. Giovanelli;L. Persani;B. Cangiano
Penultimo
;
M. Bonomi
Ultimo
2021

Abstract

: Delayed puberty (DP) defines a retardation of onset/progression of sexual maturation beyond the expected age due to either a lack/delay of the hypothalamo-pituitary-gonadal (HPG) axis activation or a gonadal failure. DP usually gives rise to concern and uncertainty in patients and their families, potentially affecting their immediate psychosocial well-being and also creating longer-term psychosexual sequelae. The most frequent form of DP in younger teenagers is self-limiting and may not need any intervention. Conversely, DP due to hypogonadism requires prompt and specific treatment that we summarize in this review. Hormone therapy primarily targets genital maturation, development of secondary sexual characteristics and the achievement of target height in line with genetic potential, but other key standards of care include body composition and bone mass. Finally, pubertal induction should promote psychosexual development and mitigate both short- and long-term impairments comprising low self-esteem, social withdrawal, depression and psychosexual difficulties. Different therapeutic options for pubertal induction have been described for both males and females but we lack the necessary larger randomized trials to define the best approaches for both sexes. We provide an in-depth and updated literature review regarding therapeutic options for inducing puberty in males and females, particularly focusing on recent therapeutic refinements that better encompass the heterogeneity of this population, and underlining key differences in therapeutic timing and goals. We also highlight persistent shortcomings in clinical practice, wherein strategies directed at "the child with delayed puberty of uncertain aetiology" risk being misapplied to older adolescents likely to have permanent hypogonadism.
GnRH deficiency; delayed puberty; estradiol; gonadotropin; idiopathic hypogonadotropic hypogonadism; testosterone
Settore MED/13 - Endocrinologia
1-dic-2021
1-dic-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
bnab043.pdf

Open Access dal 02/12/2022

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 942.35 kB
Formato Adobe PDF
942.35 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/887616
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 31
social impact